Cog­nate dou­bles man­u­fac­tur­ing ca­pac­i­ties in Mem­phis, Eu­rope, as de­mand for cell and gene ther­a­pies sky­rock­ets

5 years ago
Cell/Gene Tx
Manufacturing

Eli Lil­ly re-ups di­ver­si­ty pledge, pitch­ing in $30M to ven­ture fund for mi­nor­i­ty-owned health­care firms

5 years ago
Financing
Pharma

Look­ing to build in red-hot vi­ral vec­tor space, Ther­mo Fish­er inks $878M deal for Bel­gian man­u­fac­tur­er's 2 plants

5 years ago
Deals
Manufacturing

With its rank-and-file churn­ing out star­tups, Dana-Far­ber launch­es ven­ture fund to cap­i­tal­ize on that suc­cess

5 years ago
Financing

Can Brett Mo­nia push Io­n­is be­yond Spin­raza?

5 years ago
R&D

NextCure hires Cel­gene vet as CMO; José Ve­ga leaves Mer­ck to be­come Mod­er­na's chief safe­ty of­fi­cer

5 years ago
Peer Review

Covid-19 roundup: Hack­ers start re­leas­ing 'ma­nip­u­lat­ed' Covid-19 vac­cine docs; Ex-FDA com­mish David Kessler to ...

5 years ago
Coronavirus

In­dus­try, FDA be­gin to ham­mer out PDU­FA VII de­tails

5 years ago
FDA+

Bris­tol My­er­s' top hema­tol­ogy ex­ec is on his way out — right on the heels of a $6B CVR im­plo­sion

5 years ago
People

Am­gen tops cost watch­dog's price gougers list based on 'un­sup­port­ed' in­creas­es for En­brel with­out mean­ing­ful da­ta

5 years ago
Pharma

No­var­tis gets break­through des­ig­na­tion for Xo­lair suc­ces­sor, set­ting up spot­light for PhI­II read­out lat­er this year

5 years ago
FDA+

News brief­ing: Pre­ci­sion Med­i­cine Group ac­quires cell and gene ther­a­py-fo­cused ser­vices firm Project Far­ma; ...

5 years ago
News Briefing

As ven­ture fund­ing in on­col­o­gy flour­ish­es, neu­ro has seen shal­low­er pock­ets. A Eu­ro­pean in­vestor wants to change that

5 years ago
Financing

R&D ex­ec faces up to 10 years in prison on charges he stole “thou­sands” of top se­cret re­search doc­u­ments from ...

5 years ago
People
R&D

Fu­ji­film dou­bles down on Boston foothold, rent­ing some ma­jor legroom to chase cell and gene ther­a­pies

5 years ago
Financing
Manufacturing

Chris Garabe­di­an's first Xon­toge­ny com­pa­ny, Lan­dos Bio­phar­ma, preps a nine-fig­ure IPO as lead pro­gram heads to PhI­II

5 years ago
Financing

A much-hyped CV drug failed, re­peat­ed­ly. Now, in­vestors are bet­ting near­ly $200M on one last PhI­II bid

5 years ago
R&D

Janet Wood­cock to be act­ing FDA com­mis­sion­er while Biden team fi­nal­izes nom­i­nee — re­ports

5 years ago
People
FDA+

Mark Cuban jumps out of the Shark Tank and in­to gener­ic phar­ma with a plan to of­fer dirt-cheap drugs

5 years ago
People

Covid-19 roundup: Alex­ion's C5 in­hibitor Ul­tomiris miss­es the PhI­II bar; Lon­za in wait­ing game to use in­gre­di­ents in ...

5 years ago
Coronavirus

#JPM21: Avid­i­ty CSO Art Levin runs full speed to the clin­ic with 'dream' an­ti­body oligonu­cleotide con­ju­gate ther­a­py

5 years ago
R&D

J&J on track to roll out sin­gle-shot Covid-19 vac­cine in March, Paul Stof­fels con­firms, al­though man­u­fac­tur­ing de­lays ...

5 years ago
Coronavirus

Paint­ing by the num­bers, Sana founders carve up a gi­ant uni­corn-sized IPO — for a biotech that has­n't quite made it ...

5 years ago
Financing

Pfiz­er's in­vest­ment fund is mak­ing waves in VC — in­clud­ing a $25M bet on IBD play­er Vedan­ta Bio­sciences

5 years ago
Financing
First page Previous page 755756757758759760761 Next page Last page
A service from the Financial Times